Vascular reactivity screen of Chinese medicine danhong injection identifies danshensu as a NO-independent but PGI2-mediated relaxation factor

Journal of Cardiovascular Pharmacology

Volumn 62, Issue 5, 2013, Pages 457-465

  Wang, Dandan ^a,b   Fan, Guanwei ^a,b   Wang, Yuefei ^a,b   Liu, Haitao ^a,b   Wang, Bingyao ^a   Dong, Juan ^a,b   Zhang, Peng ^a,b   Zhang, Boli ^a   Karas, Richard H ^c   Gao, Xiumei ^a   Zhu, Yan ^a,b,c  

^a TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b Tianjin International Joint Academy of Biotechnology and Medicine   (China)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

cyclooxygenase; danhong injection; danshensu; endothelium; prostacyclin; vasorelaxation

Indexed keywords

3 (3,4 DIHYDROXYPHENYL)LACTIC ACID; CHINESE DRUG; CYCLOOXYGENASE 2; DANHONG INJECTION; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIUM DERIVED RELAXING FACTOR; ION CHANNEL; NITRIC OXIDE; PROSTACYCLIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CELL LINE; CHINESE MEDICINE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; ENDOTHELIAL DYSFUNCTION; EX VIVO STUDY; FEMALE; GENE EXPRESSION; HEART PROTECTION; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; AORTA, THORACIC; CELL LINE; CYCLOOXYGENASE 2; DRUG SYNERGISM; DRUGS, CHINESE HERBAL; ENDOTHELIAL CELLS; EPOPROSTENOL; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LACTATES; MALE; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; RATS; RATS, SPRAGUE-DAWLEY; VASODILATION;

EID: 84888127435     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182a29657     Document Type: Article

References (31)

1. Guglietta A, Guerrero M. Issues to consider in the pharmaceutical development of a cardiovascular polypill. Nat Clin Pract Cardiovasc Med. 2009;6:112-119.
2. Zhao PX, Jiang S. Effect of danhong injection on ET-1, sP-sel, and hs-CRP in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011;31: 11-14.
3. Yao JY, Zhi M, Cao WT, et al. Successful treatment with danhong injection for hepatic veno-occlusive disease. Hepatogastroenterology. 2011;58:992-995.
4. Chen ZQ, Hong L, Wang H. Effect of danhong injection on platelet activation and inflammatory factors in patients of acute coronary syndrome after intervention therapy. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2009;29:692-694.
5. Du J, Yang W, Yi D, et al. Analysis of using Danhong injection to treatment coronary heart disease patients medicines based on real world HIS database. Zhongguo Zhong Yao Za Zhi. 2011;36:2821-2824.
6. Sun M, Zhang JJ, Shan JZ, et al. Clinical observation of Danhong injection (herbal TCM product from Radix Salviae miltiorrhizae and Flos Carthami tinctorii) in the treatment of traumatic intracranial hematoma. Phytomedicine. 2009;16:683-689.
7. Fu TT, Wang CJ, Min CY, et al. Effects of danhong injection on experimental atherosclerosis rabbit model and its mechanism. Zhong Yao Cai. 2009;32:1720-1722.
8. He Y, Wan H, Du Y, et al. Protective effect of danhong injection on cerebral ischemia-reperfusion injury in rats. J Ethnopharmacol. 2012; 144:387-394.
9. Liu H, Wang S, Sun A, et al. Danhong inhibits oxidized low-density lipoprotein-induced immune maturation of dentritic cells via a peroxisome proliferator activated receptor gamma-mediated pathway. J Pharmacol Sci. 2012;119:1-9.
10. Song L, Qu HJ, Zhang XJ. Effect of danhong injection on cerebral injury in patients undergoing coronary artery bypass graft operation with extracorporeal circulation. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008;28: 705-707.
11. Zhi XW, Su XM, Feng WY, et al. Effect and mechanism of danhong injection on isolated mesenteric arterial rings in rats. Zhongguo Zhong Yao Za Zhi. 2012;37:2607-2611.
12. Csanyi G, Gajda M, Franczyk-Zarow M, et al. Functional alterations in endothelial NO, PGI (2) and EDHF pathways in aorta in ApoE/LDLR-/-mice. Prostaglandins Other Lipid Mediat. 2012;98:107-115.
13. Giles TD, Sander GE, Nossaman BD, et al. Impaired vasodilation in the pathogenesis of hypertension: focus on nitric oxide, endothelial-derived hyperpolarizing factors, and prostaglandins. J Clin Hypertens (Greenwich). 2012;14:198-205.
14. Shimokawa H, Yasutake H, Fujii K, et al. The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endotheliumdependent relaxations in rat mesenteric circulation. J Cardiovasc Pharmacol. 1996;28:703-711.
15. Zhu Y, Xia M, Yang Y, et al. Purified anthocyanin supplementation improves endothelial function via NO-cGMP activation in hypercholesterolemic individuals. Clin Chem. 2011;57:1524-1533.
16. Kwan CY, Zhang WB, Deyama T, et al. Endothelium-dependent vascular relaxation induced by Eucommia ulmoides Oliv. bark extract is mediated by NO and EDHF in small vessels. Naunyn Schmiedebergs Arch Pharmacol. 2004;369:206-211.
17. Majed BH, Khalil RA. Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn. Pharmacol Rev. 2012;64:540-582.
18. Pratico D, Dogne JM. Selective cyclooxygenase-2 inhibitors development in cardiovascular medicine. Circulation. 2005;112:1073-1079.
19. Caughey GE, Cleland LG, Penglis PS, et al. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol. 2001;167:2831-2838.
20. Liu HT, Wang YF, Olaleye O, et al. Characterization of in vivo antioxidant constituents and dual-standard quality assessment of Danhong injection. Biomed Chromatogr. 2013;27:655-663.
21. Fan G, Zhu Y, Guo H, et al. Direct vasorelaxation by a novel phytoestrogen tanshinone IIA is mediated by nongenomic action of estrogen receptor through endothelial nitric oxide synthase activation and calcium mobilization. J Cardiovasc Pharmacol. 2011;57:340-347.
22. Olszanecki R, Gebska A, Korbut R. Production of prostacyclin and prostaglandin E2 in resting and IL-1beta-stimulated A549, HUVEC and hybrid EA.HY 926 cells. J Physiol Pharmacol. 2006;57:649-660.
23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) method. Methods. 2001;25:402-408.
24. Gwozdz P, Drelicharz L, Kozlovski VI, et al. Prostacyclin, but not nitric oxide, is the major mediator of acetylcholine-induced vasodilatation in the isolated mouse heart. Pharmacol Rep. 2007;59:545-552.
25. Lam FF, Yeung JH, Chan KM, et al. Relaxant effects of danshen aqueous extract and its constituent danshensu on rat coronary artery are mediated by inhibition of calcium channels. Vascul Pharmacol. 2007;46:271-277.
26. Zhang N, Zou H, Jin L, et al. Biphasic effects of sodium danshensu on vessel function in isolated rat aorta. Acta Pharmacol Sin. 2010;31:421-428.
27. Lam FF, Deng SY, Ng ES, et al. Mechanisms of the relaxant effect of a danshen and gegen formulation on rat isolated cerebral basilar artery. J Ethnopharmacol. 2010;132:186-192.
28. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci U S A. 1992;89:7384-7388.
29. Belton O, Byrne D, Kearney D, et al. Cyclooxygenase-1 and-2-dependent prostacyclin formation in patients with atherosclerosis. Circulation. 2000; 102:840-845.
30. Ferguson S, Hebert RL, Laneuville O. NS-398 upregulates constitutive cyclooxygenase-2 expression in the M-1 cortical collecting duct cell line. J Am Soc Nephrol. 1999;10:2261-2271.
31. Ishibashi M, Bottone FG Jr, Taniura S, et al. The cyclooxygenase inhibitor indomethacin modulates gene expression and represses the extracellular matrix protein laminin gamma1 in human glioblastoma cells. Exp Cell Res. 2005;302:244-252.